Analyst firms · H.C. Wainwright · LTRN
H.C. Wainwright LTRN price target and rating history
Lantern Pharma Inc. (LTRN) · Health Care
H.C. Wainwright rates Lantern Pharma Inc. (LTRN) Buy with a $36 price target, as of its latest action on Mar 11, 2022. It has published 3 rating actions on LTRN since October 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Buy
- Price target
- $36
- Median target, all firms
- Too few
- Actions on LTRN
- 3
H.C. Wainwright price target on LTRN
Every H.C. Wainwright rating on LTRN
- Mar 11, 2022
- Nov 2, 2021
- Oct 7, 2021
Questions about H.C. Wainwright and LTRN
- What is H.C. Wainwright's price target for LTRN?
- H.C. Wainwright's latest stated price target for Lantern Pharma Inc. (LTRN) is $36, from its action on Mar 11, 2022.
- What is H.C. Wainwright's rating on LTRN?
- H.C. Wainwright rates LTRN Buy, a bullish rating, as of Mar 11, 2022.
- When did H.C. Wainwright last change its view on LTRN?
- On Mar 11, 2022, H.C. Wainwright raises its price target to $36 from $34, keeps Buy.
All H.C. Wainwright ratingsLTRN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.